Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Table 1 Clinical parameters of MM patients

Patient	Age	Sex	Type of Ig	Clinical stage			Medical history	Lenalidomide refractory
Patient	Age	Sex	Type of Ig	D&S	ISS	R-ISS	Medical history	Lenalidomide refractory
S1	68	F	IgA-κ	IIIA	III	III	Newly diagnosed	No
S2	78	M	IgG-λ	IIA	II	II	Newly diagnosed	No
S3	78	M	IgG-κ	IIIA	III	N/A	Newly diagnosed	No
S4	46	M	IgG-λ	IIIA	III	III	Newly diagnosed	No
S5	66	M	IgG-κ	IIA	I	II	Newly diagnosed	No
S6	51	F	IgG-λ	IIA	II	II	CyBorD, HDCY, BD, MEL, autoPBSCT	No
R1	56	M	IgG-κ/ BJP-κ	IA	I	N/A	VRd	Yes
R2	55	F	IgA-λ	IIA	I	II	VRd, VP16, MEL, autoPBSCT, biweeklyBor, LEN maintenance, DRd, VTDPACE, DCEP, KRd	Yes
R3	80	M	IgA-κ	IIA	I	N/A	CyBorD, Bor biweekly, VTd, VRd, HDCY, MEL, auto PBSCT	Yes
R4	73	F	BJP-λ	IIIB	III	III	Ld, Eld, DVd, PCd	Yes
R5	62	M	IgG-κ	IIIA	III	II	BD, VRd	Yes
R6	76	M	IgA-λ	IIIA	II	II	CyBorD, VRd, LEN maintenance, DVd, PCd, KRd, Kd	Yes

CyBorD; cyclophosphamide, bortezomib, dexamethasone. HDCY; High dose cyclophosphamide. BD; bortezomib, dexamethasone. MEL; melphalan. PBSCT; peripheral blood stem cell transplantation. VRd; bortezomib, lenalidomide, dexamethasone. VP-16; etoposide. Bor; bortezomib. LEN; lenalidomide. DRd; daratumumab, lenalidomide, dexamethasone. VTD-PACE; bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide. DCEP; dexamethasone, cyclophosphamide, etoposide, cisplatin. KRd; carfilzomib, lenalidomide, dexamethasone. VTd; bortezomib, thalidomide, dexamethasone. Ld; lenalidomide, dexamethasone. Eld; elotuzumab, lenalidomide, dexamethasone. DVd; daratumumab, bortezomib, dexamethasone. PCd; pomalidomide, cyclophosphamide, dexamethasone. Kd; carfilzomib, dexamethasone. D&S:Durie-Salmon staging. ISS:International Staging System. R-ISS:Revised International Staging System

ISSN: 1756-9966